Familial chronic lymphocytic leukemia: what does it mean to me?
Though B-chronic lymphocytic leukemia (CLL) is known to be a heterogeneous disease, only recently has the familial component of CLL been more thoroughly investigated. This entity is seen in approximately 5%-10% of all patients with CLL and can be associated with earlier age of diagnosis, higher female prevalence, and increased incidence of other lymphoproliferative disorders (LPDs), such as non-Hodgkin lymphoma and the more recently described monoclonal B-cell lymphocytosis CLL in family members. The prognostic parameters and clinical course of familial CLL is not clearly distinguishable from that of sporadic disease. In addition, it is not clear that the treatment responses for progressive disease has any discernible difference in familial versus sporadic CLL. The genetic etiology of CLL is unknown, and early work on familial CLL has not yet uncovered any obvious gene or group of genes that can be clearly related to the pathophysiology of CLL. However, the detailed genetic study of familial CLL is likely to be critical in uncovering relevant genes. At present it is best to indicate to concerned CLL patients that their relatives are at relatively low risk of developing CLL or other LPDs.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Susan L
SL
Slager
Neil E
NE
Kay
D000328:Adult; D017668:Age of Onset; D000368:Aged; D018450:Disease Progression; D005192:Family Health; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000150:complications; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D010375:Pedigree; D012306:Risk